{"product_id":"parkinsonian-disorders-in-clinical-practice-9781405196017","title":"Parkinsonian Disorders in Clinical Practice","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThis book gives the reader an up-to-date, clear and logical idea of what caring for parkinsonian patients entails - a challenge that clinicians will face for many years to come.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003ePreface.  \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 What is Parkinson’s disease? From pathophysiology to\u003c\/b\u003e \u003cb\u003esymptoms\u003c\/b\u003e (\u003ci\u003eAndreas Hartmann, Yves Agid, Anthony Schapira).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eI. Pathophysiology of Parkinson’s disease.\u003c\/p\u003e \u003cp\u003e1. Dysfunctions of the main neuronal pathways in Parkinson’s disease.\u003c\/p\u003e \u003cp\u003ea. An overview of neuronal systems affected in Parkinson’s disease.\u003c\/p\u003e \u003cp\u003eb. Dopaminergic neurons.\u003c\/p\u003e \u003cp\u003ec. Non-dopaminergic neurons.\u003c\/p\u003e \u003cp\u003e2. Consequences of dopaminergic neuronal lesions on basal ganglia circuits.\u003c\/p\u003e \u003cp\u003ea. The dopaminergic nigrostriatal system: pre- and postsynaptic compensatory mechanisms.\u003c\/p\u003e \u003cp\u003eb. Pathologic alterations of nigrostriatal circuits in Parkinson’s disease.\u003c\/p\u003e \u003cp\u003e3. Histopathology of Parkinson’s disease.\u003c\/p\u003e \u003cp\u003e4. The etiopathogenesis of Parkinson’s disease.\u003c\/p\u003e \u003cp\u003ea. The genetics of Parkinson’s disease: any clues for the sporadic forms?\u003c\/p\u003e \u003cp\u003eb. Relevant environmental factors: focus on mitochondria.\u003c\/p\u003e \u003cp\u003ec. Mechanisms of cell death in Parkinson’s disease: therapeutic implications.\u003c\/p\u003e \u003cp\u003e5. Conclusions.\u003c\/p\u003e \u003cp\u003ea. Parkinson’s disease or Parkinson’s syndromes?\u003c\/p\u003e \u003cp\u003eb. What Parkinson’s disease is not.\u003c\/p\u003e \u003cp\u003eII. Clinical features of Parkinson’s disease.\u003c\/p\u003e \u003cp\u003e1. Motor symptoms.\u003c\/p\u003e \u003cp\u003e2. Non-motor symptoms.\u003c\/p\u003e \u003cp\u003ea. Depression.\u003c\/p\u003e \u003cp\u003eb. Apathy.\u003c\/p\u003e \u003cp\u003ec. Cognitive impairment.\u003c\/p\u003e \u003cp\u003ed. Sleep.\u003c\/p\u003e \u003cp\u003ee. Autonomic dysfunction.\u003c\/p\u003e \u003cp\u003ef. Sensory symptoms.\u003c\/p\u003e \u003cp\u003e3. The different forms of Parkinson’s disease: relevance for prognosis.\u003c\/p\u003e \u003cp\u003e4. The differential diagnosis of Parkinson’s disease.\u003c\/p\u003e \u003cp\u003e5. Treatment-related symptoms.\u003c\/p\u003e \u003cp\u003ea. Motor complications.\u003c\/p\u003e \u003cp\u003eb. Non-motor complications.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Treatment of Parkinson’s disease (\u003c\/b\u003e\u003ci\u003eAnthony Schapira, Andreas Hartmann, Yves Agid).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eI. Antiparkinsonian agents.\u003c\/p\u003e \u003cp\u003e1. Levodopa.\u003c\/p\u003e \u003cp\u003e2. COMT inhibitors.\u003c\/p\u003e \u003cp\u003e3. Dopamine agonists.\u003c\/p\u003e \u003cp\u003e4. Monoamine oxidase B inhibitors.\u003c\/p\u003e \u003cp\u003e5. Other drugs.\u003c\/p\u003e \u003cp\u003eII. Medical management.\u003c\/p\u003e \u003cp\u003e1. Initiation of treatment.\u003c\/p\u003e \u003cp\u003e2. Maintenance of treatment (Fig. 2.7).\u003c\/p\u003e \u003cp\u003e3. Motor complications.\u003c\/p\u003e \u003cp\u003e4. Management of non-motor complications.\u003c\/p\u003e \u003cp\u003eIII. Non-medical management.\u003c\/p\u003e \u003cp\u003e1. Surgery.\u003c\/p\u003e \u003cp\u003e2. Destructive lesions.\u003c\/p\u003e \u003cp\u003e3. Cell therapy.\u003c\/p\u003e \u003cp\u003e4. Growth factors.\u003c\/p\u003e \u003cp\u003eIV. Neuroprotection.\u003c\/p\u003e \u003cp\u003e1. MAO-B inhibitors.\u003c\/p\u003e \u003cp\u003e2. Dopamine agonists.\u003c\/p\u003e \u003cp\u003e3. Coenzyme Q.\u003c\/p\u003e \u003cp\u003e4. Creatine.\u003c\/p\u003e \u003cp\u003e5. Antiapoptotic drugs.\u003c\/p\u003e \u003cp\u003eV. Conclusion.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Case studies.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eCase studies—diagnostic index.\u003c\/p\u003e \u003cp\u003eIndex.\u003c\/p\u003e","brand":"John Wiley and Sons Ltd","offers":[{"title":"Default Title","offer_id":49529339871575,"sku":"9781405196017","price":63.6,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781405196017.jpg?v=1731875238","url":"https:\/\/bookcurl.com\/products\/parkinsonian-disorders-in-clinical-practice-9781405196017","provider":"Book Curl","version":"1.0","type":"link"}